Edition:
United Kingdom

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

136.91USD
22 Mar 2019
Change (% chg)

$-1.19 (-0.86%)
Prev Close
$138.10
Open
$137.75
Day's High
$138.39
Day's Low
$136.86
Volume
2,058,477
Avg. Vol
2,739,259
52-wk High
$148.97
52-wk Low
$118.62

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.53 29.30 32.54
EPS (TTM): 5.91 -- --
ROI: 13.49 14.23 13.82
ROE: 22.63 15.46 15.25

J&J to record $700 million charge related to abandoned drug program

Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million (£536.4 million) impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176.

21 Mar 2019

J&J to record $700 million charge related to abandoned drug program

Johnson & Johnson on Thursday said it will record a nearly $700 million impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176.

21 Mar 2019

J&J to record $700 mln charge related to abandoned drug program

March 21 Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176.

21 Mar 2019

Banks stifle Wall Street rally following dovish Fed statement

NEW YORK The S&P 500 and the Dow ended lower on Wednesday as interest rate-sensitive financial stocks dragged down the indexes after the U.S. Federal Reserve affirmed a dovish monetary policy stance. | Video

20 Mar 2019

US STOCKS-FedEx outlook weighs on Wall St ahead of Fed policy decision

* Fed Chief Powell to hold press conference at 2:30 p.m. ET (Changes comment, adds details, updates prices)

20 Mar 2019

US STOCKS-Wall St drops after weak FedEx outlook; Fed on tap

* Fed Chief Powell to hold press conference at 2:30 p.m. ET (Updates to open)

20 Mar 2019

J&J and Sientra get FDA warning letters over breast implants

The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants.

19 Mar 2019

UPDATE 3-J&J and Sientra get FDA warning letters over breast implants

March 19 The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants.

19 Mar 2019

California jury awards $29 million to woman with cancer who used J&J talc

A California jury on Wednesday awarded $29 million to a woman who said that asbestos in Johnson & Johnson's talcum-powder-based products caused her cancer.

14 Mar 2019

California jury awards $29 million to woman with cancer who used J&J talc

A California jury on Wednesday awarded $29 million to a woman who said that asbestos in Johnson & Johnson's talcum-powder-based products caused her cancer.

14 Mar 2019

Earnings vs. Estimates